Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Parharidou, A."'
Autor:
Georgios Giannakoulas, Konstantinos D. Gemitzis, Georgios K. Efthimiadis, Haralampos Karvounis, Ioannis H. Styliadis, Georgios E. Parharidis, Georgios E. Louridas, Stavros Gavrielides, Soterios T. Mochlas, Georgios Giannoglou, Despina G. Parharidou
Publikováno v:
The American Journal of Cardiology. 98:1269-1272
Hypertrophic cardiomyopathy (HC) may transition to a phase characterized by systolic impairment resembling dilated cardiomyopathy. This study retrospectively assessed the incidence of left ventricular (LV) systolic impairment at initial clinical eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a839fefacd816621db7d4de185f3e4f
https://doi.org/10.1016/j.amjcard.2006.05.063
https://doi.org/10.1016/j.amjcard.2006.05.063
Autor:
Evangelos Terpos, Athina Mougiou, Alexandra Kouraklis, Aria Chatzivassili, Evridiki Michalis, Nicholas Giannakoulas, Eleni Manioudaki, Anna Lazaridou, Vassiliki Bakaloudi, Maria Protopappa, Dimitra Liapi, Elisavet Grouzi, Agapi Parharidou, Argyris Symeonidis, Garoufalia Kokkini, Nikolaos P. Laoutaris, George Vaipoulos, Nikolaos I. Anagnostopoulos, John I. Christakis, John Meletis, Konstantinos L. Bourantas, Nicholas C. Zoumbos, Xenophon Yataganas, Nora-Athina Viniou for The Greek MDS Study Grou
Publikováno v:
British Journal of Haematology. 118:174-180
Summary. Treatment with recombinant human erythropoietin (rHuEpo) improves anaemia in approximately 20% of patients with myelodysplastic syndromes (MDS). We investigated the potential advantage of a prolonged administration of rHuEpo to achieve highe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee2787cd342e537b2c174d0b1856bfc8
https://doi.org/10.1046/j.1365-2141.2002.03583.x
https://doi.org/10.1046/j.1365-2141.2002.03583.x
Autor:
John Christakis, Salem Akel, Nora Viniou, A. Galanopoulos, Effie Apostolidou, Alexandra Kouraklis, Agapi Parharidou, Xenophon Yataganas, Eurydiki Michalis, A Tasiopoulou, Georgiadou D, Dimitris Loukopoulos, E. Kritikou-Griva, Garyfallia Kokkini, N. Anagnostopoulos, E. Terpos, Argiris Symeonidis
Publikováno v:
Annals of Hematology. 81:182-186
Amifostine (AMF) promotes in vitro growth and survival of hematopoietic progenitors. In this study we evaluated the efficacy of AMF in the treatment of anemia in patients with low-risk myelodysplastic syndromes (MDS) and the possible predicting value
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7d0f45b2f11048e6dc85d739b167c54
https://doi.org/10.1007/s00277-002-0442-y
https://doi.org/10.1007/s00277-002-0442-y
Autor:
Yiannis S. Chatzizisis, Despoina Parharidou, Amalia Boufidou, Panagiotis Saravakos, Ioannis H. Styliadis
Publikováno v:
The Open Cardiovascular Medicine Journal
We report a very rare case of a patient who presented with headache as the sole symptom of an acute myocardial infarction (AMI). The patient underwent primary percutaneous coronary angioplasty followed by drug-eluting stent implantation and the heada
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3ec0dd043eb134fab516b3ed5f18d4a
https://doi.org/10.2174/1874192401004010148
https://doi.org/10.2174/1874192401004010148
Autor:
Ziakas, Antonios G., Economou, Fotios I., Charokopos, Nicholas A., Pitsis, Antonios A., Parharidou, Despina G., Papadopoulos, Thomas I., Parharidis, Georgios E.
Coronary ostial stenosis is a rare but potentially serious sequela after aortic valve replacement. It occurs in the left main or right coronary artery after 1% to 5% of aortic valve replacement procedures. The clinical symptoms are usually severe and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::29081f224644c9e1690c3effc4204dc4
https://europepmc.org/articles/PMC2929858/
https://europepmc.org/articles/PMC2929858/
Autor:
Evangelos, Terpos, Athina, Mougiou, Alexandra, Kouraklis, Aria, Chatzivassili, Evridiki, Michalis, Nicholas, Giannakoulas, Eleni, Manioudaki, Anna, Lazaridou, Vassiliki, Bakaloudi, Maria, Protopappa, Dimitra, Liapi, Elisavet, Grouzi, Agapi, Parharidou, Argyris, Symeonidis, Garoufalia, Kokkini, Nikolaos P, Laoutaris, George, Vaipoulos, Nikolaos I, Anagnostopoulos, John I, Christakis, John, Meletis, Konstantinos L, Bourantas, Nicholas C, Zoumbos, Xenophon, Yataganas, Nora-Athina, Viniou
Treatment with recombinant human erythropoietin (rHuEpo) improves anaemia in approximately 20% of patients with myelodysplastic syndromes (MDS). We investigated the potential advantage of a prolonged administration of rHuEpo to achieve higher erythro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c61b8204ae44a7164ffa211e8a957935
http://olympias.lib.uoi.gr/jspui/handle/123456789/18988
http://olympias.lib.uoi.gr/jspui/handle/123456789/18988
Treatment with recombinant human erythropoietin (rHuEpo) improves anaemia in approximately 20% of patients with myelodysplastic syndromes (MDS). We investigated the potential advantage of a prolonged administration of rHuEpo to achieve higher erythro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::622dc8a179d6c81bd3144633909128d3
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3082037
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3082037
Amifostine (AMF) promotes in vitro growth and survival of hematopoietic progenitors. In this study we evaluated the efficacy of AMF in the treatment of anemia in patients with low-risk myelodysplastic syndromes (MDS) and the possible predicting value
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::2a3fd7b40abdb2812bb54eb2acbc7c5e
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3081630
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3081630
Autor:
Agapi Parharidou, Akrivi Kostourou, John Dervenoulas, Sotos Raptis, N. Stathakis, Maria Constantinidou, Efstathios Papageorgiou, Theofanis Economopoulos
Publikováno v:
Leukemia research. 20(5)
In this prospective study, patients with "high risk' primary MDS, namely RAEB or RAEBt, were treated with combination chemotherapy (CT) supported by GM-CSF. The induction CT consisted of idarubicin 6 mg/m2 days 1-3 and cytosine-arabinoside 200 mg/m2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38883adab60be4bd20c5b021a8531ec3
https://pubmed.ncbi.nlm.nih.gov/8683977
https://pubmed.ncbi.nlm.nih.gov/8683977